Senescence

Fasano Longevity Conference Covers Politics, Investments, and Medical Research

Retrieved on: 
星期四, 十一月 9, 2023

Two hundred longevity professionals attended the 20th Annual Fasano Longevity Conference in Washington, DC.

Key Points: 
  • Two hundred longevity professionals attended the 20th Annual Fasano Longevity Conference in Washington, DC.
  • The conference, which was in hybrid format, with about 170 attending in person and 30 attending virtually, focused on a wide range of topics bearing on longevity markets, medical research, and the primary elections.
  • It covered a very interesting mix of topics bearing on longevity markets and some very cutting-edge research.” Fasano described the Conference as investor focused.
  • Next year’s Fasano Longevity Conference will be held on Monday, November 4th in Washington, DC.

Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Recipients Announced

Retrieved on: 
星期二, 四月 18, 2023

Hevolution Foundation and the American Federation for Aging Research ( AFAR ) are pleased to announce the inaugural Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research recipients.

Key Points: 
  • Hevolution Foundation and the American Federation for Aging Research ( AFAR ) are pleased to announce the inaugural Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research recipients.
  • Eighteen three-year awards of $375,000 each, for a total of $6.75 Million, have been granted to support research projects in the basic biology of aging or geroscience, a research paradigm based on addressing the biology of aging and age-related disease to promote healthy aging.
  • “Some of the biggest breakthroughs in aging research today were funded first through AFAR’s grants for promising early career researchers.
  • The Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research will significantly boost support for junior faculty worldwide,” noted Stephanie Lederman, EdM, Executive Director, AFAR.

New data by AKL Therapeutics suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing

Retrieved on: 
星期一, 三月 20, 2023

STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3

Key Points: 
  • STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3
    The study, using a human chondrocyte (cartilage-forming) cell line, was carried out at the Institute of Biomedical Research of A Coruña (INIBIC) in Spain.1 It found that APPA appears to not only reduce the number of harmful senescent cells which build up in the cartilage causing inflammation (a 'senolytic' effect), but could also potentially reverse the senescence process so cells can function normally again (a 'senomorphic' effect).1,4
    Alan Reynolds, Chief Scientific Officer at AKL Therapeutics, says: "These latest findings raise the tantalising possibility that APPA could modify the progression of debilitating OA for patients by eliminating or delaying the adverse effects of cellular senescence and the process of ageing.3
    "Frailty and mobility issues have a significant impact as we age, often leading to people living many years in pain and ill health.5,6 If we can reduce senescence, which contributes to joint damage in OA7 and is involved in many other age-related diseases, we can hopefully help improve peoples' healthspan, so they age in better physical and mental health.
  • "8
    As we age, dysfunctional senescent cells – often dubbed "zombie" cells – build up in the body while secreting harmful chemicals which cause inflammation and damage surrounding tissue – a process known as senescence.2 They have become one of the most promising targets for healthy ageing research as senescence is now known to play a major role in the development of many age-related diseases, including OA, Chronic Obstructive Pulmonary Disease (COPD), Alzheimer's Disease, Parkinson's Disease, osteoporosis, and diabetes.9
    Developing a new class of drugs called senotherapeutics to eliminate or delay the damaging effects of this cellular senescence is a new frontier in medicine.10 Senotherapeutics have the potential to increase healthspan by delaying the worse effects of ageing, which would reduce the burden of age-related diseases and could save healthcare systems billions every year.11
    David Miles, Chief Executive Officer at AKL Therapeutics, says: "With a unique mechanism of action,12-15 APPA is the only oral drug that targets the multiple signalling pathways in bone, cartilage and inflammation involved in OA, delivering pain relief to multiple joints.
  • With this latest data now showing that APPA has a potential senomorphic effect, we've recently filed a patent application and will look to carry out further studies on other senescence-related diseases to investigate its potential as a senotherapeutic."
  • APPA is an oral, patented, fixed-dose combination of two synthetically produced, synergistic, secondary metabolites of plant origin.16,17Previous human clinical trials have shown that APPA has a good safety profile, is well-tolerated and reduces pain in OA.18,19 Importantly, it has been shown to reduce levels of cartilage-damaging enzymes and levels of bone destruction.13-15 The Phase 2a trial found that those with more severe disease benefited most from APPA with a statistically significant improvement in pain vs placebo.18
    There are currently no effective and well tolerated oral therapies that provide long-term pain relief or reduce the progression of OA, a common, debilitating, degenerative disease of the joints involving the cartilage, bone, and its surrounding tissues.22 OA is the most common joint disease worldwide, affecting an estimated 10% of men and 18% of women over 60 years of age.23 Globally, the prevalent cases of OA increased by 113.25%, from 247.51 million in 1990 to 527.81 million in 2019, with OA of the knee contributing most to the overall burden.24

New data by AKL Therapeutics suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing

Retrieved on: 
星期一, 三月 20, 2023

STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3

Key Points: 
  • STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3
    The study, using a human chondrocyte (cartilage-forming) cell line, was carried out at the Institute of Biomedical Research of A Coruña (INIBIC) in Spain.1 It found that APPA appears to not only reduce the number of harmful senescent cells which build up in the cartilage causing inflammation (a 'senolytic' effect), but could also potentially reverse the senescence process so cells can function normally again (a 'senomorphic' effect).1,4
    Alan Reynolds, Chief Scientific Officer at AKL Therapeutics, says: "These latest findings raise the tantalising possibility that APPA could modify the progression of debilitating OA for patients by eliminating or delaying the adverse effects of cellular senescence and the process of ageing.3
    "Frailty and mobility issues have a significant impact as we age, often leading to people living many years in pain and ill health.5,6 If we can reduce senescence, which contributes to joint damage in OA7 and is involved in many other age-related diseases, we can hopefully help improve peoples' healthspan, so they age in better physical and mental health.
  • "8
    As we age, dysfunctional senescent cells – often dubbed "zombie" cells – build up in the body while secreting harmful chemicals which cause inflammation and damage surrounding tissue – a process known as senescence.2 They have become one of the most promising targets for healthy ageing research as senescence is now known to play a major role in the development of many age-related diseases, including OA, Chronic Obstructive Pulmonary Disease (COPD), Alzheimer's Disease, Parkinson's Disease, osteoporosis, and diabetes.9
    Developing a new class of drugs called senotherapeutics to eliminate or delay the damaging effects of this cellular senescence is a new frontier in medicine.10 Senotherapeutics have the potential to increase healthspan by delaying the worse effects of ageing, which would reduce the burden of age-related diseases and could save healthcare systems billions every year.11
    David Miles, Chief Executive Officer at AKL Therapeutics, says: "With a unique mechanism of action,12-15 APPA is the only oral drug that targets the multiple signalling pathways in bone, cartilage and inflammation involved in OA, delivering pain relief to multiple joints.
  • With this latest data now showing that APPA has a potential senomorphic effect, we've recently filed a patent application and will look to carry out further studies on other senescence-related diseases to investigate its potential as a senotherapeutic."
  • APPA is an oral, patented, fixed-dose combination of two synthetically produced, synergistic, secondary metabolites of plant origin.16,17 Previous human clinical trials have shown that APPA has a good safety profile, is well-tolerated and reduces pain in OA.18,19 Importantly, it has been shown to reduce levels of cartilage-damaging enzymes and levels of bone destruction.13-15 The Phase 2a trial found that those with more severe disease benefited most from APPA with a statistically significant improvement in pain vs placebo.18
    There are currently no effective and well tolerated oral therapies that provide long-term pain relief or reduce the progression of OA, a common, debilitating, degenerative disease of the joints involving the cartilage, bone, and its surrounding tissues.22 OA is the most common joint disease worldwide, affecting an estimated 10% of men and 18% of women over 60 years of age.23 Globally, the prevalent cases of OA increased by 113.25%, from 247.51 million in 1990 to 527.81 million in 2019, with OA of the knee contributing most to the overall burden.24

Biostarks Announces the Launch of the Groundbreaking Longevity Test Kits

Retrieved on: 
星期五, 三月 17, 2023

SOUTH JORDAN, Utah, March 17, 2023 /PRNewswire/ -- Biostarks, a digital health company, is pleased to announce the launch of its innovative at-home longevity test kits.

Key Points: 
  • SOUTH JORDAN, Utah, March 17, 2023 /PRNewswire/ -- Biostarks, a digital health company, is pleased to announce the launch of its innovative at-home longevity test kits.
  • After a successful entry in the nutrition and sport markets with two respective at-home test kits leveraging its innovative mass-spectrometry platform, the company is expanding its offering in the fast-growing longevity market with two new products in the space.
  • The base longevity at home test-kit, to be commercialized as early as of April 2023, measures intracellular NAD+ and 3 essential minerals.
  • Longevity and health enthusiasts can already pre-order their premium longevity test-kit at a preferred price on https://biostarks.com/longevity/prelaunch ahead of the summer launch.

HISTORIC FUNDRAISING - NFT DIGITAL BIO-ART CAMPAIGN

Retrieved on: 
星期五, 十一月 18, 2022

SRF is a California 501(c)(3) non-profit working on addressing aging medically through its SENS damage-repair approach (Strategies for Engineered Negligible Senescence).

Key Points: 
  • SRF is a California 501(c)(3) non-profit working on addressing aging medically through its SENS damage-repair approach (Strategies for Engineered Negligible Senescence).
  • Their campaign will highlight each of their 7-Strand research programs to challenge the 7 types of damage that cause aging.
  • In collaboration with digital artist Soliman Lopez, SRF presents VI7A a historic NFT, digital bio-art collection.
  • Each unique NFT artwork will be generated from live data streams from cell cultures by means of electrodes and an oscilloscope.

Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's

Retrieved on: 
星期三, 八月 4, 2021

The composition of matter patent secures exclusivity for a new group of iron chaperones designed to redistribute the excess iron implicated in many neurodegenerative diseases, including Alzheimer's and Parkinson's.

Key Points: 
  • The composition of matter patent secures exclusivity for a new group of iron chaperones designed to redistribute the excess iron implicated in many neurodegenerative diseases, including Alzheimer's and Parkinson's.
  • The patent, entitled "Compounds for and Methods of Treating Diseases", covers more than80 novel compounds and underwent prioritized examination by the USPTO.Together with the recent grant of Alterity's US patent No.
  • This position was further exemplified by the absence of any novelty or inventiveness objections during the course of prosecution.
  • Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people livingwith neurodegenerative diseases.

U.S. Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Patients with Dry Age-Related Macular Degeneration

Retrieved on: 
星期二, 八月 3, 2021

Phase 2a risuteganib non-exudative age-related macular degeneration (dry AMD) study are published in Ophthalmic Surgery, Lasers, and Imaging (OSLI) Retina.

Key Points: 
  • Phase 2a risuteganib non-exudative age-related macular degeneration (dry AMD) study are published in Ophthalmic Surgery, Lasers, and Imaging (OSLI) Retina.
  • Entitled Safety and Efficacy of Intravitreal Risuteganib for Non-Exudative AMD: A Multicenter, Phase 2a, Randomized, Clinical Trial , this paper describes the treatment effect of risuteganib 1.0 mg in patients with intermediate dry AMD.
  • These clinical data suggest that risuteganib can reverse vision loss and restore functional vision in patients with intermediate dry AMD with treatment at a 12-week interval.
  • Phase 2a study with risuteganib in less advanced dry AMD met its primary endpoint of vision recovery.

Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences

Retrieved on: 
星期二, 八月 3, 2021

A live webcast of the Wedbush PacGrow panel discussion will be available on the Eiger Biopharmaceuticals website at www.eigerbio.com in the Investors section.

Key Points: 
  • A live webcast of the Wedbush PacGrow panel discussion will be available on the Eiger Biopharmaceuticals website at www.eigerbio.com in the Investors section.
  • A replay of the webcast will be available approximately one hour following the live event.
  • Eigeris a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.
  • Zokinvyfor the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company's first FDA approved product.

Biophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in Sarcopenia

Retrieved on: 
星期一, 八月 2, 2021

This paves the route towards an upcoming confirmatory phase 3 study in sarcopenia and further continue the development of Sarconeos (BIO101) in this indication.

Key Points: 
  • This paves the route towards an upcoming confirmatory phase 3 study in sarcopenia and further continue the development of Sarconeos (BIO101) in this indication.
  • Stanislas Veillet, CEO of Biophytis said: Despites COVID-19 pandemic, the SARA team has been able to demonstrate the potential of Sarconeos (BIO101) in sarcopenia.
  • We are now committed to progress Sarconeos (BIO101) into phase 3 either alone or through partnerships with pharmaceutical companies.
  • Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements.